Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

被引：0
|
作者：
Andrew Rowland
Mafalda M Dias
Michael D Wiese
Ganessan Kichenadasse
Ross A McKinnon
Christos S Karapetis
Michael J Sorich
机构：
[1] School of Medicine,Department of Clinical Pharmacology
[2] Flinders University,undefined
[3] Flinders Centre for Innovation in Cancer,undefined
[4] School of Medicine,undefined
[5] Flinders University,undefined
[6] School of Pharmacy and Medical Sciences,undefined
[7] University of South Australia,undefined
来源：
British Journal of Cancer | 2015年 / 113卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1635 / 1635
相关论文
共 50 条
  • [31] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Tomokazu Kishiki
    Hiroaki Ohnishi
    Tadahiko Masaki
    Kouki Ohtsuka
    Yasuo Ohkura
    Jyunji Furuse
    Takashi Watanabe
    Masanori Sugiyama
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 749 - 757
  • [32] Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials
    Kagawa, Y.
    Kotani, D.
    Bando, H.
    Takahashi, N.
    Horita, Y.
    Kanazawa, A.
    Kato, T.
    Ando, K.
    Satake, H.
    Shinozaki, E.
    Sunakawa, Y.
    Takashima, A.
    Yamazaki, K.
    Yuki, S.
    Nakajima, H.
    Nakamura, Y.
    Wakabayashi, M.
    Taniguchi, H.
    Ohta, T.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S244 - S244
  • [33] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Ohnishi, Hiroaki
    Masaki, Tadahiko
    Ohtsuka, Kouki
    Ohkura, Yasuo
    Furuse, Jyunji
    Watanabe, Takashi
    Sugiyama, Masanori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 749 - 757
  • [34] Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer
    Rowland, Andrew
    Karapetis, Christos S.
    Mangoni, Arduino A.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    McKinnon, Ross A.
    Sorich, Michael J.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S31 - S34
  • [35] BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
    Mao, Chen
    Liao, Ru-Yan
    Qiu, Li-Xin
    Wang, Xi-Wen
    Ding, Hong
    Chen, Qing
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (04) : 2219 - 2223
  • [36] BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
    Chen Mao
    Ru-Yan Liao
    Li-Xin Qiu
    Xi-Wen Wang
    Hong Ding
    Qing Chen
    Molecular Biology Reports, 2011, 38 : 2219 - 2223
  • [37] Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
    Astrid Lièvre
    Bérèngere Ouine
    Jim Canet
    Aurélie Cartier
    Yael Amar
    Wulfran Cacheux
    Odette Mariani
    Rosine Guimbaud
    Janick Selves
    Thierry Lecomte
    Serge Guyetant
    Ivan Bieche
    Frédérique Berger
    Leanne de Koning
    British Journal of Cancer, 2018, 119 : 387 - 387
  • [38] Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
    Kagawa, Yoshinori
    Kotani, Daisuke
    Bando, Hideaki
    Takahashi, Naoki
    Hamaguchi, Tetsuya
    Kanazawa, Akiyoshi
    Kato, Takeshi
    Ando, Koji
    Satake, Hironaga
    Shinozaki, Eiji
    Sunakawa, Yu
    Takashima, Atsuo
    Yamazaki, Kentaro
    Yuki, Satoshi
    Nakajima, Hiromichi
    Nakamura, Yoshiaki
    Wakabayashi, Masashi
    Taniguchi, Hiroya
    Ohta, Takashi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
    Harle, A.
    Salleron, J.
    Perkins, G.
    Pilati, C.
    Blons, H.
    Laurent-Puig, P.
    Merlin, J. L.
    BRITISH JOURNAL OF CANCER, 2015, 113 (04) : 680 - 685
  • [40] Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
    A Harlé
    J Salleron
    G Perkins
    C Pilati
    H Blons
    P Laurent-Puig
    J L Merlin
    British Journal of Cancer, 2015, 113 : 680 - 685
12345